Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Greg Jenkins who wrote (610)	3/24/1999 4:46:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Excerpts from Merrill Lynch's report of March 22 on Celexa: We now forecast that Celexa revenue can exceed $1.0 Billion during 2003, which would represent an average 19% share of total prescriptions. Our estimates are more conservative than physicians expectations and take into account the possibility that they overestimate their actual usage because of early enthusiasm for Celexa. Warner-Lambert, who is co-promoting Celexa for three years, will hare in the profits of the product on an escalating basis until 2001, after which the profit split to WLA declines. [WLA will continue to enjoy a profit split from Celexa hereafter.] We are conservatively forecasting contributions from Forest Labs of $37 million in 1999, $70 million in 2000 and $102 million in 2001.